CAMURUS AB
39Patents
36Active
39Granted
53Portfolio score
Filing activity: Nov 14, 1988 → Oct 28, 2024 · 14 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8541400B2 | Compositions forming non-lamellar dispersions | Human Necessities | 61 | Active |
| US8236755B2 | Opioid depot formulations | Human Necessities | 35 | Active |
| US8097239B2 | Controlled-release formulations | Human Necessities | 35 | Active |
| US8236292B2 | Liquid depot formulations | Human Necessities | 27 | Active |
| US8546326B2 | Glp-1 analogue formulations | Human Necessities | 20 | Active |
| US8182834B2 | Ternary non-lamellar lipid compositions | Human Necessities | 12 | Active |
| US8187629B2 | Non-lamellar compositions of DOPE and P80 | Human Necessities | 12 | Expired |
| US5001062A | Antithrombogenic article containing lysozyme and heparin adsorbed on a substrate | Human Necessities | 10 | Expired |
| US9585959B2 | Robust controlled-release formulations | Human Necessities | 9 | Active |
| US5260282A | Saliva substitute | Human Necessities | 8 | Expired |
| US8920782B2 | Topical bioadhesive formulations | Human Necessities | 6 | Active |
| US9526788B2 | Pharmaceutical lipid compositions | Human Necessities | 6 | Active |
| US9968680B2 | Topical bioadhesive formulations | Human Necessities | 5 | Active |
| US9937164B2 | Opioid formulations | Human Necessities | 5 | Active |
| US9649382B2 | Topical bioadhesive formulations | Human Necessities | 5 | Active |
| US10912772B2 | Opioid formulations | Human Necessities | 4 | Active |
| US10688148B2 | Formulations containing a somatostatin receptor agonist | Emerging Cross-Sectional Technologies | 4 | Active |
| US11135215B2 | Opioid formulations | Human Necessities | 2 | Active |
| US11110084B2 | Opioid formulations | Human Necessities | 2 | Active |
| US9974861B2 | Peptide slow-release formulations | Human Necessities | 2 | Active |
| US11135264B2 | Formulations containing a somatostatin receptor agonist | Emerging Cross-Sectional Technologies | 1 | Active |
| US8865021B2 | Compositions of lipids and cationic peptides | Emerging Cross-Sectional Technologies | 1 | Active |
| US9820934B2 | Acid containing lipid formulations | Human Necessities | 1 | Active |
| US9067190B2 | Method for loading amphiphile particles with active agents | Performing Operations; Transporting | 1 | Active |
| US12029813B2 | Injectable buprenorphine formulation | Human Necessities | 1 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.